Jefferies Group set a $248.00 price target on Shire PLC (NASDAQ:SHPG) in a research note issued to investors on Friday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on SHPG. Zacks Investment Research upgraded Shire PLC from a sell rating to a hold rating in a research note on Thursday, August 4th. Citigroup Inc. restated a buy rating on shares of Shire PLC in a research note on Tuesday, September 27th. BNP Paribas restated a buy rating on shares of Shire PLC in a research note on Sunday, October 23rd. JPMorgan Chase & Co. restated an overweight rating on shares of Shire PLC in a research note on Monday, August 1st. Finally, Guggenheim reaffirmed a neutral rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Four analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $222.06.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Shares of Shire PLC (NASDAQ:SHPG) opened at 181.04 on Friday. The stock has a 50 day moving average of $0.00 and a 200-day moving average of $0.00. Shire PLC has a 12 month low of $147.60 and a 12 month high of $219.52.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share for the quarter, missing the consensus estimate of $3.21 by $0.04. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. The company had revenue of $3.45 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter last year, the business posted $3.24 earnings per share. Shire PLC’s revenue was up 108.6% on a year-over-year basis. On average, analysts anticipate that Shire PLC will post $12.96 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the last quarter. Canal Insurance CO purchased a new stake in Shire PLC during the second quarter worth $102,000. FTB Advisors Inc. increased its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. purchased a new stake in Shire PLC during the second quarter worth $111,000. Finally, Ropes Wealth Advisors LLC purchased a new stake in Shire PLC during the second quarter worth $114,000. Institutional investors own 24.62% of the company’s stock.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.